Expect Repatha and Praluent to Be Saved as Add-On Meds for High Cholesterol

You'll hear buzz about using the "PCSK9 inhibitors," Repatha (evolocumab) and Praluent (alirocumab), in patients with heart disease.

New evidence suggests that adding the cholesterol med Repatha to a statin in patients with heart disease and other risks (diabetes, etc) prevents future cardiovascular events.

But don't expect to see a lot more Rxs for PCSK9 inhibitors yet.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote